About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Sofra™
RNA Vaccines and Therapeutics
Autoimmune Disease
Scientific Background
Chroma™
Clinical Trials
Publications & Events
Investor Centre
Share Price
ASX Announcements
Presentations & Interviews
Annual Reports
Financial Reports
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Media Centre
Investor Videos
Overview
Newsletters
Coverage
Investor Videos
NOX Insights
Noxopharm Podcasts
Investor Videos
Noxopharm CEO Discusses Subsidiary, Pharmorage with Proactive Investors
December 22, 2021
Noxopharm 2021 AGM
November 17, 2021
Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results
Aug 24, 2021
Noxopharm Presents at Broker Briefing 1 July 2021
Jul 5, 2021
V-Con: Biotech - Noxopharm (ASX:NOX)
Jul 1, 2021
Noxopharm's Dr Graham Kelly outlines its four pillars oncology strategy (proactiveinvestors.com.au)
May 20, 2021
Noxopharm Presents to Share Café Hidden Gems Webinar
May 17, 2021
How Noxopharm is harnessing the power of the immune system with Veyonda®
Sep 10, 2020
Interview with Proactive: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial
Apr 23, 2021
The Inside Network Interview with NOX CEO
Apr 27, 2021
Noxopharm DARRT Treatment Animation
Nov 17, 2020
Veyonda
®
Mode of Action Animation
Nov 17, 2020
See more videos
